Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with short ...
Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial programme ...
This is the second of five long vowel programmes in our series of videos that explore the sounds of English. This is the second of eight other consonant programmes in our series of videos that explore ...
This is the second of five long vowel programmes in our series of videos that explore the sounds of English. This is the second of eight other consonant programmes in our series of videos that explore ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback